All the latest about our company

  • Meet us at the Düsseldorf-Jülich Symposium 2023

    December 4, 2023

    Oliver Bannach, CEO of attyloid, will present at the 5th Düsseldorf-Jülich Symposium on Neurodegenerative Diseases, themed "Amyloid, from early aggregation ...

  • sFIDA Technology Reveals New Insights into Protein Aggregation in Psychotic Disorders

    September 5, 2023

    In a pioneering study that could have wide-reaching implications for psychiatric research, scientists have employed attyloid’s surface-based Fluorescence Intensity Distribution ...

  • attyloid’s sFIDA Technology Key in Revealing COVID-19’s Potential Neurodegenerative Impact

    August 21, 2023

    A new study has utilized attyloid's cutting-edge Single Molecule Fluorescence Intensity Distribution Analysis (sFIDA) technology to explore how COVID-19 may ...

  • Recent Study Validates Alzheimer’s Treatment in Beagle Models, Credits sFIDA Technology for Precise Quantification of Tau Aggregates

    July 29, 2023

    In a significant new study focusing on Alzheimer's Disease (AD), researchers have highlighted the disease-modifying effects of RD2, a potential ...

  • New Publication Highlights Enhancement of attyloid’s sFIDA Technology Through Internal Quality Control Standards

    May 10, 2023

    attyloid's recent publication has outlined the establishment of an internal quality control (IQC) standard aimed at improving the robustness of ...

  • Meet us at Neuro 4D

    April 21, 2023

    The Neuro4D conference takes place in Mainz, Germany on May 15-16, 2023. With a focus on drug discovery for proteopathic ...

  • attyloid’s sFIDA Used in Detecting Parkinson’s-Related Biomarkers in Stool Samples

    February 2, 2023

    A recent study published in Nature Parkinson’s Diease  has used attyloid's sFIDA technology to measure α-synuclein aggregates in stool, a ...

Categories

  • Publications

    5

  • Press Releases

    0

  • News

    0

  • Events

    2